scholarly journals Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non–Small Cell Lung Cancer

2018 ◽  
Vol 16 (5) ◽  
pp. 508-516 ◽  
Author(s):  
Vivek Verma ◽  
Amy C. Moreno ◽  
Waqar Haque ◽  
Penny Fang ◽  
Steven H. Lin
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Surgical Margin ◽  
Small Cell ◽  
Chemoradiation Therapy ◽  
Margin Status ◽  
Concurrent Chemoradiation ◽  
Small Cell Lung ◽  
Concurrent Chemoradiation Therapy

Induction concurrent chemoradiation therapy for invading apical non-small cell lung cancer

2004 ◽  
Vol 52 (3) ◽  
pp. 120-126 ◽  
Author(s):  
Shinichiro Miyoshi ◽  
Keiji Iuchi ◽  
Kenji Nakamura ◽  
Katsuhiro Nakagawa ◽  
Hajime Maeda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Chemoradiation Therapy ◽  
Concurrent Chemoradiation ◽  
Small Cell Lung ◽  
Concurrent Chemoradiation Therapy

scholarly journals Combination of chemoradiation therapy with immunotherapy in the treatment of patients with inoperable stage III non-small cell lung cancer

2020 ◽  
pp. 209-214
Author(s):  
N. V. Marinichenko ◽  
K. K. Laktionov ◽  
A. V. Nazarenko ◽  
E. V. Reutova ◽  
Merab S. Ardzinba ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Chemoradiation Therapy ◽  
Concurrent Chemoradiation ◽  
Stage Iii ◽  
Small Cell Lung ◽  
Concurrent Chemoradiation Therapy

For more than 10 years, there have been no significant improvements in treatment outcomes for patients with inoperable locally advanced non-small cell lung cancer. At the moment, the standard of treatment for this category of patients is concurrent chemoradiation therapy. At the same time, the 5-year overall survival rate varies in the range of 15–25%. This indicator contributes to the modernization of existing approaches, as well as the search for new ways in the treatment of patients with inoperable stage III non-small cell lung cancer.One of the promising areas is the combination of chemoradiation therapy with immunotherapy. Thus, the use of Imfinzi (durvalumab, AstraZeneca) as a consolidation therapy in the Phase III clinical trial PACIFIC demonstrated a reduction in the risk of death by about one third in comparison with the standard approach.We present a clinical case study of a patient with locally advanced non-small cell lung cancer who received treatment in the framework of concurrent chemoradiation therapy followed by immunotherapy with durvalumab, continuing until now. The result of the therapy is the complete response to the specific treatment, recorded according to PET-CT.Thus, the use of immunotherapy as consolidation therapy represents a promising strategy for improving outcomes after concurrent chemoradiation therapy in patients with inoperable stage III non-small cell lung cancer

Sign in / Sign up

Export Citation Format

Share Document